Serum Levels of Plasminogen Activator Inhibitor-1 in Patients with Parkinson’s Disease

• Published in: Medical principles and practice Vol. 33; no. 6; pp. 562 - 568
• Main Authors: Tanrikulu, Azra Meryem, Ozdilek, Betul, Agirbasli, Mehmet
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.12.2024
• Subjects: Aged; Alzheimer's disease; Biomarkers; Case-Control Studies; Dopamine; Dyskinesia; Education; Enzyme-Linked Immunosorbent Assay; Family medical history; Female; Humans; Hypertension; Male; Males; Middle Aged; Original Paper; Outpatient care facilities; Parkinson Disease - blood; Pathogenesis; Pathophysiology; Plasminogen Activator Inhibitor 1 - blood; Posture; Severity of Illness Index; Tremor (Muscular contraction); Serum; PAI-1; Neurodegeneration; Parkinson’s disease
• ISSN: 1011-7571; 1423-0151; 1423-0151
• DOI: 10.1159/000540854

Abstract Objectives: The aim of the study was to investigate serum plasminogen activator inhibitor-1 (PAI-1) levels of patients with Parkinson’s disease (PD) and their relationship with clinical findings and treatment of disease. Methods: The study included 125 PD patients and 48 healthy controls. Patients have been taking effective dopaminergic treatment regularly. The clinical severity of parkinsonism was assessed using the Hoehn and Yahr (HY) staging scale and the Unified PD Rating Scale (UPDRS). PAI-1 level analysis was performed by enzyme-linked immunosorbent assay. Results: Patients with PD had significantly lower serum PAI-1 levels than healthy controls (p < 0.001). Correlations with clinical findings showed only a marginally positive correlation between serum PAI-1 and HY score (r = 0.170, p = 0.05). In contrast, no significant correlation was demonstrated with the UPDRS score or other clinical parameters. Conclusion: This is the first comprehensive analysis of serum PAI-1 levels in patients with PD. The distribution of PAI-1 in PD appears to be complex. The study results implicate that the paradoxical effects of tissue plasminogen activator on the brain parenchyma can be important in the pathophysiology of PD. Future studies are needed to elucidate the role of fibrinolytic system components in PD.